PRECIGEN, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PRECIGEN, INC. stock issued during period, value, stock options exercised for the quarter ending 2017-12-31 was $113.00K, a 88.53% decline year-over-year.
- PRECIGEN, INC. stock issued during period, value, stock options exercised for the quarter ending 2017-09-30 was $189.00K, a 62.87% decline year-over-year.
- PRECIGEN, INC. stock issued during period, value, stock options exercised for the quarter ending 2017-06-30 was $503.00K, a 88.41% decline year-over-year.
- PRECIGEN, INC. stock issued during period, value, stock options exercised for the quarter ending 2017-03-31 was $175.00K, a 98.69% decline year-over-year.
- PRECIGEN, INC. stock issued during period, value, stock options exercised for fiscal 2017 was $980.00K, a 94.89% decline from fiscal 2016.
- PRECIGEN, INC. stock issued during period, value, stock options exercised for fiscal 2016 was $19.16M, a 32.52% increase from fiscal 2015.
- PRECIGEN, INC. stock issued during period, value, stock options exercised for fiscal 2015 was $14.46M, a 871.26% increase from fiscal 2014.
- PRECIGEN, INC. stock issued during period, value, stock options exercised for fiscal 2014 was $1.49M.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2017-12-31 | $113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $980.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | $189.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $1.85M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $503.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $2.17M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $175.00K 10-Q · filed 2017-05-10 | $6.01M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $985.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $19.16M 10-K · filed 2019-03-01 |
| 2016-09-30 | $509.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $20.43M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $4.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $21.75M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $13.33M 10-Q · filed 2016-05-10 | $25.23M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $14.46M 10-K · filed 2018-03-01 |
| 2015-09-30 | $1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $12.42M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $7.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $10.89M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $2.57M 10-Q · filed 2015-05-11 | $3.73M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $215.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $1.49M 10-K · filed 2017-03-01 |
| 2014-09-30 | $298.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | |
| 2014-06-30 | $646.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | |
| 2014-03-31 | $330.00K 10-Q · filed 2014-05-09 | |
| 2012-12-31 | $473.00K 10-K · filed 2015-03-02 | |
| 2011-12-31 | $184.00K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |